These emerging medications , Semaglutide , represent a groundbreaking advancement in addressing obesity and potentially other ailments . These drugs are categorized as GLP-1 receptor stimulators, indicating they to emulate the endogenous GLP-1 peptide, stimulating metabolic release and suppressin